ROBERT ALEXANDER INGRAM - 16 Dec 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role: FORMER DIRECTOR
Signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol: BDTX
Transactions as of: 16 Dec 2022
Net transactions value: +$14,062
Form type: 4
Filing time: 19 Dec 2022, 20:14:26 UTC
Previous filing: 02 Dec 2022
Next filing: 02 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDTX	Common Stock	Award	$14,062	+9,375	+28%	$1.50	42,854	16 Dec 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

ROBERT ALEXANDER INGRAM is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2	The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022.

Remarks:

This "Exit" Form 4 is voluntarily filed to report that the Reporting Person is no longer serving in the role as the Company's director, effective as of December 13, 2022, and therefore is no longer subject to Section 16 reporting. The grant included herein relates to compensation for the role of the Reporting Person as a director prior to his resignation.